In-hospital mortality, comorbidities, and costs of one million mechanically ventilated patients in Germany: a nationwide observational study before, during, and after the COVID-19 pandemic

IF 13.6 Q1 HEALTH CARE SCIENCES & SERVICES
Christian Karagiannidis , Franz Krause , Claas Bentlage , Johannes Wolff , Thomas Bein , Wolfram Windisch , Reinhard Busse
{"title":"In-hospital mortality, comorbidities, and costs of one million mechanically ventilated patients in Germany: a nationwide observational study before, during, and after the COVID-19 pandemic","authors":"Christian Karagiannidis ,&nbsp;Franz Krause ,&nbsp;Claas Bentlage ,&nbsp;Johannes Wolff ,&nbsp;Thomas Bein ,&nbsp;Wolfram Windisch ,&nbsp;Reinhard Busse","doi":"10.1016/j.lanepe.2024.100954","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Even more than hospital care in general, intensive care and mechanical ventilation capacities and its utilization in terms of rates, indications, ventilation types and outcomes vary largely among countries. We analyzed complete and nationwide data for Germany, a country with a large intensive care sector, before, during and after the COVID-19 pandemic.</p></div><div><h3>Methods</h3><p>Analysis of administrative claims data, provided by the German health insurance, from all hospitals for all individual patients who were mechanically ventilated between 2019 and 2022. The data included age, sex, diagnoses, length of stay, procedures (e.g., form and duration of mechanical ventilation), outcome (dead vs. alive) and costs. We included all patients who were at least 18 years old at the time of discharge from January 1st, 2019 to December 31st, 2022. Patients were grouped according to year, age group and the form of mechanical ventilation. We further analyzed subgroups of patients being resuscitated and those being COVID-19 positive (vs. negative).</p></div><div><h3>Findings</h3><p>During the four years, 1,003,882 patients were mechanically ventilated in 1395 hospitals. Rates per 100,000 inhabitants varied across age groups from 110 to 123 (18–59 years) to 1101–1275 (&gt;80 years). The top main diagnoses were other forms of heart diseases, pneumonia, chronic obstructive pulmonary disease (COPD), ischemic heart diseases and cerebrovascular diseases. 43.3% (437,031/1,003,882) of all mechanically ventilated patients died in hospital with a remarkable increase in mortality with age and from 2019 to 2022 by almost 5%-points. The in-hospital mortality of ventilated COVID-19 patients was 53.7% (46,553/86,729), while it was 42.6% (390,478/917,153) in non-COVID patients. In-hospital mortality varied from 27.0% in non-invasive mechanical ventilation (NIV) only to 53.4% in invasive mechanical ventilation only cases, 59.4% with early NIV failure, 68.6% with late NIV failure, to 74.0% in patients receiving VV-ECMO and 80.0% in VA-ECMO. 17.5% of mechanically ventilated patients had been resuscitated before, of whom 78.2% (153,762/196,750) died. Total expenditure was around 6 billion Euros per year, i.e. 0.17% of the German GDP.</p></div><div><h3>Interpretation</h3><p>Mechanical ventilation was widely used, before, during and after the COVID-19 pandemic in Germany, reaching more than 1000 patients per 100,000 inhabitants per year in the age over 80 years. In-hospital mortality rates in this nationwide and complete cohort exceeded most of the data known by far.</p></div><div><h3>Funding</h3><p>This research did not receive any dedicated funding.</p></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001212/pdfft?md5=6c4f99a3fe6499bf043569f2bba9511e&pid=1-s2.0-S2666776224001212-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Regional Health-Europe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666776224001212","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Even more than hospital care in general, intensive care and mechanical ventilation capacities and its utilization in terms of rates, indications, ventilation types and outcomes vary largely among countries. We analyzed complete and nationwide data for Germany, a country with a large intensive care sector, before, during and after the COVID-19 pandemic.

Methods

Analysis of administrative claims data, provided by the German health insurance, from all hospitals for all individual patients who were mechanically ventilated between 2019 and 2022. The data included age, sex, diagnoses, length of stay, procedures (e.g., form and duration of mechanical ventilation), outcome (dead vs. alive) and costs. We included all patients who were at least 18 years old at the time of discharge from January 1st, 2019 to December 31st, 2022. Patients were grouped according to year, age group and the form of mechanical ventilation. We further analyzed subgroups of patients being resuscitated and those being COVID-19 positive (vs. negative).

Findings

During the four years, 1,003,882 patients were mechanically ventilated in 1395 hospitals. Rates per 100,000 inhabitants varied across age groups from 110 to 123 (18–59 years) to 1101–1275 (>80 years). The top main diagnoses were other forms of heart diseases, pneumonia, chronic obstructive pulmonary disease (COPD), ischemic heart diseases and cerebrovascular diseases. 43.3% (437,031/1,003,882) of all mechanically ventilated patients died in hospital with a remarkable increase in mortality with age and from 2019 to 2022 by almost 5%-points. The in-hospital mortality of ventilated COVID-19 patients was 53.7% (46,553/86,729), while it was 42.6% (390,478/917,153) in non-COVID patients. In-hospital mortality varied from 27.0% in non-invasive mechanical ventilation (NIV) only to 53.4% in invasive mechanical ventilation only cases, 59.4% with early NIV failure, 68.6% with late NIV failure, to 74.0% in patients receiving VV-ECMO and 80.0% in VA-ECMO. 17.5% of mechanically ventilated patients had been resuscitated before, of whom 78.2% (153,762/196,750) died. Total expenditure was around 6 billion Euros per year, i.e. 0.17% of the German GDP.

Interpretation

Mechanical ventilation was widely used, before, during and after the COVID-19 pandemic in Germany, reaching more than 1000 patients per 100,000 inhabitants per year in the age over 80 years. In-hospital mortality rates in this nationwide and complete cohort exceeded most of the data known by far.

Funding

This research did not receive any dedicated funding.

德国 100 万机械通气患者的院内死亡率、合并症和费用:COVID-19 大流行之前、期间和之后的全国性观察研究
背景与一般的医院护理相比,重症监护和机械通气的能力及其利用率、适应症、通气类型和结果在很大程度上因国家而异。我们分析了德国这个重症监护领域大国在 COVID-19 大流行之前、期间和之后的完整全国性数据。方法分析了德国医疗保险提供的行政报销数据,这些数据来自所有医院在 2019 年至 2022 年期间接受机械通气的所有患者。数据包括年龄、性别、诊断、住院时间、程序(如机械通气的形式和持续时间)、结果(死亡与存活)和费用。我们纳入了 2019 年 1 月 1 日至 2022 年 12 月 31 日出院时至少年满 18 岁的所有患者。根据年份、年龄组和机械通气形式对患者进行分组。我们进一步分析了复苏患者和 COVID-19 阳性(与阴性)患者的分组情况。研究结果在这四年中,1395 家医院对 1003882 名患者进行了机械通气。每 100,000 名居民中,各年龄组的发病率从 110 到 123(18-59 岁)不等,从 1101 到 1275(80 岁)不等。最主要的诊断是其他形式的心脏病、肺炎、慢性阻塞性肺病(COPD)、缺血性心脏病和脑血管疾病。43.3%(437,031/1,003,882)的机械通气患者死于医院,死亡率随着年龄的增长而显著增加,从2019年到2022年增加了近5%个百分点。COVID-19 通气患者的院内死亡率为 53.7%(46,553/86,729),而非 COVID 患者的院内死亡率为 42.6%(390,478/917,153)。仅接受无创机械通气(NIV)的患者的院内死亡率为 27.0%,仅接受有创机械通气的患者的院内死亡率为 53.4%,NIV 早期失败的患者的院内死亡率为 59.4%,NIV 晚期失败的患者的院内死亡率为 68.6%,接受 VV-ECMO 的患者的院内死亡率为 74.0%,接受 VA-ECMO 的患者的院内死亡率为 80.0%。17.5%的机械通气患者之前接受过复苏,其中78.2%(153762/196750)的患者死亡。每年的总支出约为 60 亿欧元,占德国国内生产总值的 0.17%。释义在 COVID-19 大流行之前、期间和之后,机械通气在德国被广泛使用,每年每 10 万名居民中有超过 1000 名 80 岁以上的患者。在这个全国性的完整队列中,院内死亡率超过了目前已知的大多数数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
19.90
自引率
1.40%
发文量
260
审稿时长
9 weeks
期刊介绍: The Lancet Regional Health – Europe, a gold open access journal, is part of The Lancet's global effort to promote healthcare quality and accessibility worldwide. It focuses on advancing clinical practice and health policy in the European region to enhance health outcomes. The journal publishes high-quality original research advocating changes in clinical practice and health policy. It also includes reviews, commentaries, and opinion pieces on regional health topics, such as infection and disease prevention, healthy aging, and reducing health disparities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信